MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
3.200
+0.160
+5.26%
After Hours: 3.200 0 0.00% 17:00 09/30 EDT
OPEN
3.060
PREV CLOSE
3.040
HIGH
3.360
LOW
3.055
VOLUME
2.15M
TURNOVER
0
52 WEEK HIGH
18.69
52 WEEK LOW
2.960
MARKET CAP
599.70M
P/E (TTM)
-1.1308
1D
5D
1M
3M
1Y
5Y
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as LY3471851 or NKTR-358) in patients with atopic dermatitis (AD) and plaque psoriasis at the 2022 European A...
PR Newswire · 09/07 05:15
Nektar Therapeutics's Return On Capital Employed Insights
Nektar Therapeutics (NASDAQ:NKTR) brought in sales totaling $21.59 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 75.97%, resulting in a loss of $159.07 million.
Benzinga · 08/23 14:04
Nektar Therapeutics (NASDAQ:NKTR shareholders incur further losses as stock declines 11% this week, taking five-year losses to 75%
While it may not be enough for some shareholders, we think it is good to see the Nektar Therapeutics ( NASDAQ:NKTR...
Simply Wall St. · 08/21 13:57
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on natura...
PR Newswire · 08/16 12:30
--JPMorgan Downgrades Nektar Therapeutics to Underweight From Neutral
--JPMorgan Downgrades Nektar Therapeutics to Underweight From Neutral
MT Newswires · 08/08 05:28
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.
Zacks · 08/05 16:11
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 15.84% and 7.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 22:15
Recap: Nektar Therapeutics Q2 Earnings
Nektar Therapeutics (NASDAQ:NKTR) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 08/04 21:46
More
About NKTR
Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Webull offers kinds of Nektar Therapeutics stock information, including NASDAQ:NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.